(Z)-3-(3-Cyano-phenyl)-4-(2H-pyrazol-3-yl)-but-2-enoic acid ethyl ester | 474334-47-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (Z)-3-(3-Cyano-phenyl)-4-(2H-pyrazol-3-yl)-but-2-enoic acid ethyl ester
• CAS: 474334-47-9
• 化学式: C₁₆H₁₅N₃O₂
• 分子量: 281.314
• InChiKey: NAERAHBIMDBXAG-UVTDQMKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.47
• 重原子数：
  21.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  78.77
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (Z)-3-(3-Cyano-phenyl)-4-(2H-pyrazol-3-yl)-but-2-enoic acid ethyl ester 在 盐酸 、 甲醇 、 ammonium acetate 、 三甲基铝 作用下， 以 二氯甲烷 为溶剂， 生成 (Z)-3-(3-Carbamimidoyl-phenyl)-4-(2H-pyrazol-3-yl)-but-2-enoic acid (2'-sulfamoyl-biphenyl-4-yl)-amide
  参考文献：
  名称：

  Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors

  摘要：

  Substituted acrylamides were used as templates that bridge P1 and P4 binding elements, resulting in a series of potent sub-nanomolar) and selective factor Xa inhibitors. In this template, cis-geometry of P1 and P4 ligands is highly preferred. SAR on the substituting groups, as well as on modification of P1 and P4 moieties is described. Compounds in this series show good in vivo efficacy in animal models. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00199-3
• 作为产物：
  描述：

  3-Oxo-4-(2H-pyrazol-3-yl)-butyric acid ethyl ester 在 potassium phosphate 、 四(三苯基膦)钯 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 (Z)-3-(3-Cyano-phenyl)-4-(2H-pyrazol-3-yl)-but-2-enoic acid ethyl ester
  参考文献：
  名称：

  Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors

  摘要：

  Substituted acrylamides were used as templates that bridge P1 and P4 binding elements, resulting in a series of potent sub-nanomolar) and selective factor Xa inhibitors. In this template, cis-geometry of P1 and P4 ligands is highly preferred. SAR on the substituting groups, as well as on modification of P1 and P4 moieties is described. Compounds in this series show good in vivo efficacy in animal models. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00199-3